Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data
Abstract Atezolizumab is a treatment for metastatic urothelial carcinoma (mUC), yet only 23% of mUC patients benefit from it. Worse yet, accurately predicting such responders remains challenging, despite existing biomarkers. Here we employed eight machine learning (ML) algorithms to predict mUC pati...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-00969-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850222299601436672 |
|---|---|
| author | Chayanit Piyawajanusorn Ghita Ghislat Pedro J. Ballester |
| author_facet | Chayanit Piyawajanusorn Ghita Ghislat Pedro J. Ballester |
| author_sort | Chayanit Piyawajanusorn |
| collection | DOAJ |
| description | Abstract Atezolizumab is a treatment for metastatic urothelial carcinoma (mUC), yet only 23% of mUC patients benefit from it. Worse yet, accurately predicting such responders remains challenging, despite existing biomarkers. Here we employed eight machine learning (ML) algorithms to predict mUC patient response to atezolizumab using tumours’ gene expression profiling and clinical data from two independent cohorts. The CART-OMC model developed on the discovery dataset achieved the highest performance, with a validation set Matthews correlation coefficient (MCC) of 0.437, using the expressions of just 29 ML-selected genes, including CXCL9 and IFNG. Univariate biomarkers like TMB, TNB, and PD-L1 were less predictive with MCCs of 0, 0.316, and 0, respectively. Upon merging these datasets, the best-performing model (LGBM-OMC; MCC of 0.252) also outperformed top modelling approaches such as EaSIeR (MCC ~ 0) and JADBio (MCC of 0.179). We make these promising ML models freely available to predict atezolizumab response in other mUC patients. |
| format | Article |
| id | doaj-art-049298ce6b294ae4bbc6a4511eb83df9 |
| institution | OA Journals |
| issn | 2397-768X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Precision Oncology |
| spelling | doaj-art-049298ce6b294ae4bbc6a4511eb83df92025-08-20T02:06:23ZengNature Portfolionpj Precision Oncology2397-768X2025-06-019111410.1038/s41698-025-00969-8Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical dataChayanit Piyawajanusorn0Ghita Ghislat1Pedro J. Ballester2Department of Bioengineering, Imperial College LondonDepartment of Bioengineering, Imperial College LondonDepartment of Bioengineering, Imperial College LondonAbstract Atezolizumab is a treatment for metastatic urothelial carcinoma (mUC), yet only 23% of mUC patients benefit from it. Worse yet, accurately predicting such responders remains challenging, despite existing biomarkers. Here we employed eight machine learning (ML) algorithms to predict mUC patient response to atezolizumab using tumours’ gene expression profiling and clinical data from two independent cohorts. The CART-OMC model developed on the discovery dataset achieved the highest performance, with a validation set Matthews correlation coefficient (MCC) of 0.437, using the expressions of just 29 ML-selected genes, including CXCL9 and IFNG. Univariate biomarkers like TMB, TNB, and PD-L1 were less predictive with MCCs of 0, 0.316, and 0, respectively. Upon merging these datasets, the best-performing model (LGBM-OMC; MCC of 0.252) also outperformed top modelling approaches such as EaSIeR (MCC ~ 0) and JADBio (MCC of 0.179). We make these promising ML models freely available to predict atezolizumab response in other mUC patients.https://doi.org/10.1038/s41698-025-00969-8 |
| spellingShingle | Chayanit Piyawajanusorn Ghita Ghislat Pedro J. Ballester Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data npj Precision Oncology |
| title | Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data |
| title_full | Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data |
| title_fullStr | Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data |
| title_full_unstemmed | Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data |
| title_short | Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data |
| title_sort | predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data |
| url | https://doi.org/10.1038/s41698-025-00969-8 |
| work_keys_str_mv | AT chayanitpiyawajanusorn predictingatezolizumabresponseinmetastaticurothelialcarcinomapatientsusingmachinelearningonintegratedtumourgeneexpressionandclinicaldata AT ghitaghislat predictingatezolizumabresponseinmetastaticurothelialcarcinomapatientsusingmachinelearningonintegratedtumourgeneexpressionandclinicaldata AT pedrojballester predictingatezolizumabresponseinmetastaticurothelialcarcinomapatientsusingmachinelearningonintegratedtumourgeneexpressionandclinicaldata |